Literature DB >> 2555438

The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region.

G Laux1, A Economou, P J Farrell.   

Abstract

The intact terminal protein genes (TP1 and TP2) of Epstein-Barr virus (EBV) are created upon infection by circularization of the linear viral genome at its terminal repeats. The structure of the 1.7 kb TP2 latent mRNA has been determined by cDNA analysis and Northern blotting, revealing its close relation to TP1 mRNA. The 1.7 kb transcript is expressed from a different promoter and has a different 5' exon from TP1 but is also spliced across the terminal repeats. The last eight exons are common to the TP1 and TP2 RNAs. The TP2 promoter is 3.3 kb downstream of the TP1 promoter and is part of a bidirectional latent EBV promoter region transcribing the TP2 and the latent membrane protein RNAs in opposite directions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555438     DOI: 10.1099/0022-1317-70-11-3079

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  34 in total

1.  Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus.

Authors:  D Salamon; M Takacs; D Ujvari; J Uhlig; H Wolf; J Minarovits; H H Niller
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.

Authors:  R Longnecker; C L Miller; X Q Miao; A Marchini; E Kieff
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter.

Authors:  Rongsheng Peng; Stephanie C Moses; Jie Tan; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression.

Authors:  S F Tsang; F Wang; K M Izumi; E Kieff
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

5.  Minimal protein domain requirements for the intracellular localization and self-aggregation of Epstein-Barr virus latent membrane protein 2.

Authors:  Monica Jo Tomaszewski-Flick; David T Rowe
Journal:  Virus Genes       Date:  2007-06-13       Impact factor: 2.332

6.  Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene.

Authors:  U Zimber-Strobl; K O Suentzenich; G Laux; D Eick; M Cordier; A Calender; M Billaud; G M Lenoir; G W Bornkamm
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

7.  Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction.

Authors:  S Fruehling; S K Lee; R Herrold; B Frech; G Laux; E Kremmer; F A Grässer; R Longnecker
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Authors:  Christopher P Fox; Tracey A Haigh; Graham S Taylor; Heather M Long; Steven P Lee; Claire Shannon-Lowe; Simon O'Connor; Catherine M Bollard; Javeed Iqbal; Wing C Chan; Alan B Rickinson; Andrew I Bell; Martin Rowe
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

9.  An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking.

Authors:  C L Miller; J H Lee; E Kieff; R Longnecker
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

10.  Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes.

Authors:  C L Miller; R Longnecker; E Kieff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.